The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth

Oncotarget

Volumn 4, Issue 10, 2013, Pages 1632-1646

  Kurenova, Elena ^a,c   Liao, Jianqun ^a   He, Di Hua ^b   Hunt, Darrell ^b   Yemma, Michael ^a   Bshara, Wiam ^a   Seshadri, Mukund ^a   Cance, William G ^a,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c CureFAKtor Pharmaceuticals   (United States)

Author keywords

FAK Scaffold Inhibitor; FAK VEGFR 3 interaction; Pancreatic cancer; Protein protein interaction

Indexed keywords

FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SMALL MOLECULE CHLOROPYRAMINE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOSTASIS; DEPHOSPHORYLATION; DOSE RESPONSE; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; ETHYLENEDIAMINES; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, SCID; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886734971     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1365     Document Type: Article

References (50)

1. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM and Tuveson DA. Stromal biology and therapy in pancreatic cancer. Gut. 2011; 60(6):861-868.
2. Kim EJ and Simeone DM. Advances in pancreatic cancer. Current Opinion in Gastroenterology. 2011; 27(5):460-466 410.1097/MOG.1090b1013e328349e328331f.
3. Vaccaro V, Melisi D, Bria E, Cuppone F, Ciuffreda L, Pino MS, Gelibter A, Tortora G, Cognetti F and Milella M. Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin Ther Targets. 2011; 15(10):1183-1196.
4. Warsame R and Grothey A. Treatment options for advanced pancreatic cancer: a review. Expert Review of Anticancer Therapy. 2012; 12(10):1327-1336.
5. Garber K. Stromal depletion goes on trial in pancreatic cancer. J Natl Cancer Inst. 2010; 102(7):448-450.
6. Provenzano PP and Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer. 2013; 108(1):1-8.
7. Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H and Manabe T. Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation. Molecular Cancer. 2005; 4(1):37.
8. Ucar DA, Dang LH and Hochwald SN. Focal adhesion kinase signaling and function in pancreatic cancer. Front Biosci (Elite Ed). 2011; 3:750-756.
9. Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, Chang J, Simkins S and Xu L. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res. 2000; 6(6):2417-2423.
10. Lark AL, Livasy CA, Calvo B, Caskey L, Moore DT, Yang X and Cance WG. Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses. Clin Cancer Res. 2003; 9(1):215-222.
11. Zhao J and Guan J-L. Signal transduction by focal adhesion kinase in cancer. Cancer and Metastasis Reviews. 2009; 28(1):35-49.
12. Furuyama K, Doi R, Mori T, Toyoda E, Ito D, Kami K, Koizumi M, Kida A, Kawaguchi Y and Fujimoto K. Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J Surg. 2006; 30(2):219-226.
13. Chatzizacharias NA, Giaginis C, Zizi-Serbetzoglou D, Kouraklis GP, Karatzas G and Theocharis SE. Evaluation of the clinical significance of focal adhesion kinase and SRC expression in human pancreatic ductal adenocarcinoma. Pancreas. 2010; 39(6):930-936.
14. Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE. Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery. 2004; 135(5):555-562.
15. Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW and Whang EE. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun. 2003; 311(3):786-792.
16. Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W and Tonghua L. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Molecular Cancer. 2009; 8(1):125.
17. Schultze A and Fiedler W. Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase. Anticancer Agents Med Chem. 2011; 11(7):593-599.
18. Stokes JB, Adair SJ, Slack-Davis J, Walters DM, Tilghman RW, Hershey ED, Lowrey B, Thomas KS, Bouton AH, Hwang RF, Stelow EB, Parsons JT and Bauer TW. Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment. Molecular Cancer Therapeutics. 2011.
19. Fan H, Zhao X, Sun S, Luo M and Guan J-L. Focal adhesion kinase scaffolding function to mediate endophilin A2 phosphorylation promotes epithelial-mesenchymal transition and mammary cancer stem cell activities in vivo. Journal of Biological Chemistry. 2013.
20. Cance WG, Kurenova E, Marlowe T and Golubovskaya V. Disrupting the Scaffold to Improve Focal Adhesion Kinase-Targeted Cancer Therapeutics. Sci Signal. 2013; 6(268):pe10-.
21. Kozakov D, Hall DR, Chuang G-Y, Cencic R, Brenke R, Grove LE, Beglov D, Pelletier J, Whitty A and Vajda S. Structural conservation of druggable hot spots in proteinâ"protein interfaces. Proceedings of the National Academy of Sciences. 2011; 108(33):13528-13533.
22. Ucar DA, Cox A, He DH, Ostrov DA, Kurenova E and Hochwald SN. A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma. Anticancer Agents Med Chem. 2011; 11(7):629-637.
23. Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, Magis A, Ostrov D, Cance WG and Golubovskaya VM. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle. 2009; 8(15):2435-2443.
24. Garces CA, Kurenova EV, Golubovskaya VM and Cance WG. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Cancer Res. 2006; 66(3):1446-1454.
25. Kubo H, Fujiwara T, Jussila L, Hashi H, Ogawa M, Shimizu K, Awane M, Sakai Y, Takabayashi A, Alitalo K, Yamaoka Y and Nishikawa SI. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood. 2000; 96(2):546-553.
26. Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, Steiner P, Hicklin D, Persaud K, Tonra JR, Witte L and Alitalo K. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 2007; 67(2):593-599.
27. Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Yla-Herttuala S, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008; 454(7204):656-660.
28. Alitalo K and Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 2002; 1(3):219.
29. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T and Alitalo K. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005; 65(11):4739-4746.
30. Tang RF, Itakura J, Aikawa T, Matsuda K, Fujii H, Korc M and Matsumoto Y. Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer. Pancreas. 2001; 22(3):285-292.
31. Von Marschall Z, Scholz A, Stacker SA, Achen MG, Jackson DG, Alves F, Schirner M, Haberey M, Thierauch KH, Wiedenmann B and Rosewicz S. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer. Int J Oncol. 2005; 27(3):669-679.
32. Schneider M, Buchler P, Giese N, Giese T, Wilting J, Buchler MW and Friess H. Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread. Int J Oncol. 2006; 28(4):883-890.
33. Su JL, Yen CJ, Chen PS, Chuang SE, Hong CC, Kuo IH, Chen HY, Hung MC and Kuo ML. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer. 2007; 96(4):541-545.
34. Morelli MP, Brown AM, Pitts TM, Tentler JJ, Ciardiello F, Ryan A, Jürgensmeier JM and Eckhardt SG. Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Molecular Cancer Therapeutics. 2009; 8(9):2546-2558.
35. Kurenova EV, Hunt DL, He D, Fu AD, Massoll NA, Golubovskaya VM, Garces CA and Cance WG. Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo. Cell Cycle. 2009; 8(14).
36. Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, Sproat G, Swann R, Gray N, Ryan A, Jürgensmeier JM and Womack C. Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers. Clinical Cancer Research. 2010; 16(14):3548-3561.
37. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T and Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst. 2002; 94(11):819-825.
38. Thiele W and Sleeman JP. Tumor-induced lymphangiogenesis: A target for cancer therapy? Journal of Biotechnology. 2006; 124(1):224.
39. Kurenova EV, Hunt DL, He D, Magis AT, Ostrov DA and Cance WG. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J Med Chem. 2009; 52(15):4716-4724.
40. Kabir J, Lobo M and Zachary I. Staurosporine induces endothelial cell apoptosis via focal adhesion kinase dephosphorylation and focal adhesion disassembly independent of focal adhesion kinase proteolysis. Biochem J. 2002; 367(Pt 1):145-155.
41. van de Water B, Nagelkerke JF and Stevens JL. Dephosphorylation of Focal Adhesion Kinase (FAK) and Loss of Focal Contacts Precede Caspase-mediated Cleavage of FAK during Apoptosis in Renal Epithelial Cells. J Biol Chem. 1999; 274(19):13328-13337.
42. Mihaljevic AL, Michalski C, Friess H and Kleeff Jr. Molecular mechanism of pancreatic cancer: understanding proliferation, invasion, and metastasis. Langenbeck's Archives of Surgery. 2010; 395(4):295-308.
43. Mitra SK, Hanson DA and Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005; 6(1):56-68.
44. Zhao X and Guan J-L. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Advanced Drug Delivery Reviews. 2011; 63(8):610-615.
45. Salameh A, Galvagni F, Bardelli M, Bussolino F and Oliviero S. Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood. 2005; 106(10):3423-3431.
46. Yamamoto D, Sonoda Y, Hasegawa M, Funakoshi-Tago M, Aizu-Yokota E and Kasahara T. FAK overexpression upregulates cyclin D3 and enhances cell proliferation via the PKC and PI3-kinase-Akt pathways. Cell Signal. 2003; 15(6):575-583.
47. Bourgeas Rl, Basse M-J, Morelli X and Roche P. Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database. PLoS ONE. 2010; 5(3):e9598.
48. Betzi Sp, Guerlesquin Fo and Morelli X. (2009). Protein-Protein Interaction Inhibition (2P2I): Fewer and Fewer Undruggable Targets. Combinatorial Chemistry & High Throughput Screening, pp. 968-983.
49. Golubovskaya VM, Huang G, Ho B, Yemma M, Morrison CD, Lee J, Eliceiri BP and Cance WG. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide. Mol Cancer Ther. 2013; 12(2):162-172.
50. Ucar DA, Kurenova E, Garrett TJ, Cance WG, Nyberg C, Cox A, Massoll N, Ostrov DA, Lawrence N, Sebti SM, Zajac-Kaye M and Hochwald SN. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Cell Cycle. 2012; 11(17):3250-3259.